PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Infusion Pumps”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 127 records · Page 7Linked to original sources
PubMed1999

The effect of syringe size on the performance of an infusion pump.

This study investigated the effect of using three different sized syringes on the accuracy of fluid delivery when using an infusion pump at low infusion rates (1 ml.h-1). The study also measured the influence of the syringe size on the time to occlusion alarm, and on the size of the subsequent bolus dose that might be infused after relief of the occlusion which triggered the alarm. The use of a larger size syringe was found not to affect the accuracy of infusate delivery, but delayed the time to occlusion alarm and increased the size of the postocclusion bolus dose.

Equipment Design↗
PubMed2001

[Hemodynamic effects of propofol induction administered with target controlled infusion pump in patients scheduled for open heart surgery].

Target controlled infusion systems have been developed to provide improved convenience and control during intravenous anaesthesia. The anaesthetist sets and adjust the target blood concentration and depth of anaesthesia--as required on clinical grounds. Infusion rates are altered automatically according to a validated pharmacokinetic model. Haemodynamic effects during induction of anaesthesia with target controlled infusion pump have been documented in this prospective study. Twenty patients scheduled for open heart surgery. Mean age 62.2 +/- 9.93 years. The surgical procedures were: 16 coronary bypass, 2 artificial valve replacement, 2 coronary bypass combined valve replacement. Anaesthesia was induced with alfentanil, 20-40 micrograms/kg, and propofol administered with target control infusion pump, 1.5-4 micrograms/ml target concentration. Pulse contour analysis was used for haemodynamic measurements. They were repeated before induction (T0), after induction--before intubation (T1), after intubation in two minutes intervals (T2-T5). Compared with values obtained in awake patients, there was a significant decrease in mean arterial pressure (-30%), in cardiac output (-25%), in heart rate (-8%), in vascular resistance (-9%), in contractility (-37.4%), in stroke volume (-17.5%). No ECG changes were observed during that period. The haemodynamic changes observed do not differ from the published data in patients presenting for cardiac surgery and anaesthetized with manually controlled infusion techniques using propofol.

Aged↗
PubMedDate not supplied

Evaluation of infusion pumps and controllers.

An evaluation of infusion pumps and controllers is being undertaken for the UK Department of Health and Social Security within the Bath District Health Authority. The technical performance and safety assessments are being made at the Bath Institute of Medical Engineering, and the user assessment at various hospitals in the Bath area. The first batch assessed was constituted of devices which achieve control by means of detecting drip-rate (the Frenshore IC2 and Ivac 231 controllers and the Imed 911, Ivac 531, Graseby Dynamics MP20 and Vickers (DC2 pumps), and the second batch to be assessed was constituted of syringe pumps (the Braun Perfusors ED2 and V1, Fresenius Injectomat 30 and 50, Graseby Dynamics MS16 and its MS18 variant, Sage 242A and its 242E and 240E variants, and Vickers Treonic 1 P3). The results of these assessments were reported in 'Health Equipment Information' ('HE1') 96 (September 1981) and 106 (October 1982) respectively. We reproduce below a review of controlled infusion techniques, from the first report, and extracts of the report of the assessment of syringe pumps.

Equipment Design↗
PubMed2001

The surgical aspects of the totally implantable hepatic artery infusion pump.

The design of a totally implantable hepatic artery infusion pump in 1969 made the use of hepatic artery infusion feasible and practical as a treatment for patients with hepatic neoplasms. The implantable pumps could function for long periods and reliably infuse a measured quantity of drug into the hepatic artery in a continuous fashion. This enabled oncologists to give much higher doses of chemotherapy directly into the blood supply of the tumors as well as to use a continuous infusion schedule.

Antineoplastic Agents↗
PubMedDate not supplied

A rabbit model for implanting continuous drug infusion pumps.

This paper describes a surgical technique for implanting a readily available, human-sized drug infusion pump in rabbits. We developed this technique in order to expand uses of implantable infusion pump technology in the laboratory. The dog, which has been the research animal of choice in previous studies using implantable pumps, can now be replaced by smaller, less expensive animals for similar or other laboratory purposes. This technique can be of particular importance in the study of atherosclerosis where the dog is a poor model and the rabbit an excellent one. In 18 rabbits with inferior vena cava cannulations, we were able to obtain 100% survival and constant solution delivery for up to and greater than 6 months. This technique is safe and reproducible. By employing a simple catheter modification and using special pump anchoring precautions, we found that we could successfully use a human-sized device in rabbit studies. Commentary is also made concerning the relative contributions to patency and vein sclerosis of catheter diameter and the infusate media.

Animals↗
PubMed2000

Is an infusion pump necessary to safely administer remifentanil?

UNLABELLED: We sought to determine if remifentanil could be administered as safely and effectively from an IV drip as from a calculator pump, because not all anesthesiologists have access to a calculator pump. Forty healthy adults undergoing outpatient knee arthroscopy were premedicated with midazolam, 2 mg. Total IV anesthesia was induced with propofol by bolus (2 mg/kg) and maintained by a continuous infusion of propofol and remifentanil. On a randomized, double-blinded basis, they received, IV, either remifentanil (50 microg/mL) by syringe from an infusion pump or from a bag of saline containing remifentanil 20 microg/mL through a minidrip set. The remifentanil infusion syringe pump rate was 0.4 microg. kg(-1). min(-1) until skin incision and then 0.2 microg. kg(-1). min(-1), whereas that from the bag/minidrip set was set to approximate the delivery rate from the pump. Both a syringe pump and bag/minidrip set infusion were administered to each patient but only one contained remifentanil, that one being determined in a randomized, double-blinded manner. There were no differences in demographic data, time to recovery of open eyes, response to command, ability to speak (approximately 7 min), total dose and time of administration of propofol and remifentanil, the incidence of intraoperative hypotension and bradycardia, and postoperative shivering. We demonstrated that remifentanil can be administered as safely and effectively from a bag with a minidrip set as from a syringe in a calculator infusion pump, provided the anesthesiologist is paying attention to the drip rate from the bag. IMPLICATIONS: Because remifentanil is rapidly degraded in the body, it can be safely and effectively administered from a bag through a minidrip set. We showed that there was no difference with this less expensive method of administration than from the more precise method of a calculator infusion pump.

Adolescent↗
PubMed2002

Treatment of patients who have type 1 diabetes mellitus: physiological misconceptions and infusion pump therapy.

BACKGROUND: This article reviews the unique physiology of patients who have type 1 diabetes mellitus (insulin-dependent diabetes mellitus, or IDDM); allays some common physiological misconceptions; and updates dental practitioners on the emerging technology of insulin infusion pump therapy, now available to patients who have type 1 diabetes mellitus. DESCRIPTION: The authors review the physiology of stress and describe the dawn phenomenon. They also describe insulin infusion pump therapy, as well as its advantages and disadvantages, to familiarize dentists with new technologies in caring for patients who have diabetes. Emergencies that may present themselves as a result of these advances in biotechnology are discussed. CLINICAL IMPLICATIONS: Dental practitioners who treat patients who have IDDM need to have a solid foundation in the basic medical sciences and emerging biomedical technology as they each relate to diabetes. Practitioners must become familiar with infusion pump therapy, not only for cases of medical emergencies, but also to customize treatment for patients who have diabetes. Practitioners also need to remain up to date in the rapidly changing realm of caring for people who have diabetes.

Acute Disease↗
PubMed2001

Are you putting patients in danger? Heed warning on infusion pumps.

During on-site surveys in 2001, surveyors will be asking about your use of infusion pumps. The ED is at higher risk for errors and adverse outcomes than other departments because of the types of drugs given and time constraints. Do not use pumps without protection from the free-flow of intravenous fluid/medication into the patient. If your hospital is considering a change in infusion pumps, make sure someone from the ED is involved in the product evaluation.

Emergency Service, Hospital↗
PubMed1994

Hyperbaric oxygen therapy: implications for spinal cord injury patients with intrathecal baclofen infusion pumps. Case report.

A patient with a cervical spinal cord injury receiving intrathecal baclofen for spasticity control underwent a 7 week course of hyperbaric oxygen therapy to induce healing of an ischial decubitus ulcer. After completion of this treatment and during a routine baclofen infusion pump refill, the actual pump reservoir volume exceeded computer measurements obtained with telemetry. Examination of the physiology of hyperbaric oxygen therapy in relation to infusion pump function revealed that the intraspinal pressures attained during hyperbaric oxygen therapy produced retrograde leakage of cerebrospinal fluid into the infusion pump reservoir.

Adult↗
PubMed1986

Controlled studies of a new microprocessor-based portable infusion pump.

A new microprocessor-controlled portable infusion pump, the Pancretec Provider IV 2000 TM was tested in vitro and in vivo in cancer patients. The Provider is a rotary peristaltic, battery-powered pump capable of flow rates of 0.2 to 83 ml/hour with delivery volumes up to 1999 ml. Two programming modes are available: intermittent infusion and continuous infusion. Bench tests showed the flow rate accuracy to be within 96% of the desired rate. Flow rate precision was similarly excellent at +/- 2%. Clinical studies were performed in 14 ambulatory patients receiving continuous infusion antineoplastic or analgesic drugs over 5-60 days as outpatients. The majority of infusions delivered fluoropyrimidines via indwelling central venous access ports. Two of the patients received long term (60 days) continuous infusion of analgesics for pain control. Flow rate accuracy with the pumps was within +/- 5% in 90% of the 27 infusion courses (244 patient-days of continuous infusion therapy). A significant therapy deviation (interruption 10% of the desired course) occurred in three instances. One related to a procedural error (incomplete cartridge insertion into the pump), two were caused by fluid leakage which interrupted pump function. Defect alarms (both visual and audible) operated in both instances. A KVO flow rate of 0.1 ml/hr was also found to be adequate to maintain catheter patency in peripheral veins over a 24-hour period in two normal volunteers. We conclude that the Provider pump is an accurate, reliable and state of the art infusion system with wide clinical applicability.

Adult↗
PubMed1992

Stability of ondansetron hydrochloride in portable infusion-pump reservoirs.

The stability of ondansetron hydrochloride 0.24 and 2 mg/mL when delivered by portable infusion pump at near-body temperature over various time periods was investigated. Nine 100-mL drug reservoirs were prepared, three containing ondansetron hydrochloride 2 mg/mL and six containing ondansetron hydrochloride diluted with 0.9% sodium chloride injection to 0.24 mg/mL. Three of the reservoirs containing the diluted solution were refrigerated for up to 30 days at 3 degrees C before being attached to portable infusion pumps and pumped over 24 hours at 30 degrees C. The remaining six reservoirs were attached to pumps immediately after being filled, and the solutions were delivered for up to 24 hours (the diluted solution; three reservoirs) or up to seven days (the concentrated solution; three reservoirs) at 30 degrees C. Samples were taken initially and periodically and analyzed by high-performance liquid chromatography and with a pH meter. Both the diluted and the concentrated solutions of ondansetron hydrochloride retained at least 95% of the initial drug concentration under all the conditions studied. There was no appreciable change in pH. Ondansetron hydrochloride 0.24 mg/mL was stable when stored for up to 30 days at 3 degrees C and infused over 24 hours at 30 degrees C. Ondansetron hydrochloride 2 mg/mL was stable when infused for up to one week at 30 degrees C.

Chromatography, High Pressure Liquid↗